The use of molecular signatures to add value to standard clinical and pathological parameters has impacted clinical practice in many cancer types, but perhaps most notably in the breast cancer field. This is, in part, due to the considerable complexity of the disease at the clinical, morphological and molecular levels. The adoption of molecular profiling of DNA, RNA and protein continues to reveal important differences in the intrinsic biology between molecular subtypes and has begun to impact the way patients are managed. Several bioinformatic tools have been developed using DNA or RNA-based signatures to stratify the disease into biologically and/or clinically meaningful subgroups. Here, we review the approaches that have been used to develop gene expression signatures into currently available diagnostic assays (e.g. OncotypeDX® and Mammaprint®), plus we describe the latest work on genome sequencing, the methodologies used in the discovery process of mutational signatures, and the potential of these signatures to impact the clinic.
Introduction
Breast cancer is an extremely diverse and complex disease, and is one of the leading causes of death amongst women. There is marked tumour heterogeneity between patients, with specific breast cancer subtypes associated with differing prognoses.
Differentiating breast tumour types is a key component of the clinical management process to ensure patients are given the most appropriate type of therapy. In this review we briefly illustrate the best practices in tumour classification from a pathology context, including currently utilised predictive and prognostic biomarkers.
We will then highlight the advances made in the molecular arena, which have shed light onto the differences in intrinsic biology between subtypes of the disease and how these have been developed into molecular signatures with clinical utility.
Pathological Classification of Disease
As part of the diagnostic process, a pathologist examines a tissue biopsy or resection specimen. A diagnosis will be made based on key parameters, which include histological type, tumour grade, and tumour stage using criteria outlined by the World Health Organisation (WHO) [1] . There are at least 20 different histological subtypes of breast cancer, which display differences in morphology and growth pattern. Grading of breast cancer is performed using the Nottingham grading system [2, 3] . This is a three-tiered scoring system, assessing the number of visible mitoses, the presence of tumour cells creating tubule structures and evidence of nuclear pleomorphism. The number of mitoses acts as a surrogate for growth rate, while tubule formation is a measure of whether the tumour tissue resembles normal-like ductal structures. Pleomorphism is a measure of the size, shape and variability of tumour nuclei. The prognostic value of the grading system in predicting behaviour and patient outcome has long been established [4, 5] . A histological grade 1, welldifferentiated tumour is associated with a significantly better prognosis compared to a grade 3, poorly differentiated tumour.
Tumour Stage is a measure of how far the tumour has spread, and so is also a highly prognostic tool. The American Joint Committee on Cancer (AJCC) TNM staging system is used for most organ systems, including breast. T is a measure of the tumour size (<2cm, between 2-5cm and >5 cm) and whether the tumour has invaded the chest wall; N refers to the number of lymph nodes that show evidence of cancer (0, 1-3, 4-9, >10) and the position of the node in the nodal system; and M is a measure of distant metastasis, i.e. if there is a sign of cancer spread beyond the site of the primary tumour.
Clinical biomarkers in breast cancer
Biomarkers play important roles in diagnosis and prediction of prognosis, and may also represent therapeutic targets. Key breast cancer biomarkers include Oestrogen Receptor (ER), Progesterone Receptor (PR) and Human Epidermal Growth factor Receptor 2 (HER2/ERBB2); these markers have been reviewed extensively and their expression correlates with differences in tumour behaviour and patient outcome and the potential response to targeted endocrine therapy or HER2 therapy [6] . The protein expression levels of ER, PR and HER2 are assessed using immunohistochemistry and, in addition, the ERBB2 gene copy number is also quantified using in situ hybridization [7] . If a breast cancer is positive for either ER or PR the breast cancer is termed as Hormone Receptor positive (HR+) and these patients will likely receive endocrine therapy, while patients with HER2+ breast cancers will receive trastuzumab or other HER2 targeted therapies. According to the Surveillance, Epidemiology, and End Results (SEER) survey that covers 28% of the North American population, 72 .7% of breast cancer patients had HR+/HER2-disease, 14.9% had HER2+ disease (of which, 10.3% were HR+/HER2+ and 4.6% were HR-/HER2+) and 12.2% had triple-negative disease [8] . As the name suggests, triple-negative breast cancer (TNBC) encompasses all tumours that are negative for ER, PR and HER2. The majority of TNBC are high-grade and aggressive tumours associated with a poorer outcome than other breast cancer subtypes, despite a good response to chemotherapy [9] .
Ki67 is a proliferative marker used to predict tumour growth rate, which has been shown to be a prognostic biomarker with predictive ability in the adjuvant context [10] [11] [12] [13] [14] . Ki-67 staining has not yet been fully translated to the clinical setting owing to difficulties in standardising technical aspects of the procedure, including appropriate scoring methods and thresholds [15, 16] .
A combination of the 4 IHC based biomarkers (ER, PR, HER2 and Ki67) exists as a protein-based 'signature'. This panel was termed IHC4 and the algorithm has been validated as a predictor of risk of distant recurrence in breast cancer [17, 18] .
Although the current well-established clinical variables mentioned above show associations with prognosis and outcome, there are increasing concerns that these variables are limited in their ability to capture the diversity of breast cancer and tailor the therapy to individual patients.
Various methods have been developed to help improve the management of breast cancer patients based on the combination of this clinical, pathological and biomarker data that is collected at diagnosis. Various tools have been developed (e.g. Adjuvant! Online, Predict, the Nottingham Prognostic Index (NPI)) to help inform clinicians about their patient's potential prognosis and whether they are likely to benefit from adjuvant therapy following breast cancer surgery. These mathematical algorithms incorporate various clinical and pathological variables described above (patient age, tumour size, grade and lymph node status) together with tumour expression of these molecular biomarkers (ER, HER2 and Ki67) to predict survival with or without adjuvant therapy. The NPI is a highly prognostic tool based on combining pathological parameters of tumour size, tumour grade and the number of axillary lymph nodes that are involved with tumour. The NPI Plus was recently developed to incorporate a panel of 10 immunohistochemical biomarkers of demonstrated prognostic significance [19] . This modification identifies prognostic subgroups within the well-described molecular subtypes of disease (ER+, HER2+ or triple negative) and so may provide additional benefit to managing the individual patient.
Developing mRNA based gene classifiers
Gene expression profiling of breast cancer has illustrated that the disease exhibits significant molecular heterogeneity, even among tumours with the same morphological features. This has led to the development of classification tools to stratify tumours into diverse molecular subtypes that have clinical relevance. To briefly illustrate the power of this approach, the early analysis of just 84 breast tumours by hierarchical clustering using genes whose expression levels differed from the median revealed several molecular subtypes of disease, including the Luminal A, Luminal B, Her2-enriched and Basal-like, as well as a normal-like group [20] . Each of these subtypes is clinically important as they exhibit differences in incidence, prognosis and response to therapies [21] . For example ER+ breast tumours are a heterogeneous group, which can be stratified, in simple terms, into Luminal A and B subtypes. The luminal A subtype has the best prognosis, whereas the Luminal B subtype collectively describes an aggressive group of tumours with a higher proliferative index indicated by Ki67 or Aurora A kinase (AURKA) staining. The amplification and overexpression of HER2 contributes to this aggressive behaviour in some Luminal B tumours [22] along with the activation of a plethora of other oncogenes found in regions of recurrent gene amplification (e.g. at 8p11-12 and 11q13) [23] . This work has therefore had a significant impact on the way breast cancer is described, researched and managed clinically. The classification of these 'intrinsic' subtypes has evolved since this first description, and they can now be defined by a 50 gene quantitative measurement known as the PAM50 subtype classifier [21] , which is commercially packaged as a diagnostic classification tool A single sample predictor (SSP) is a strategy that has been employed in order to best classify an individual tumour into one of several predefined molecular subtypes, such as those mentioned above. The idea being that an individual tumour can be classified based on how similar its gene expression profile associates with the molecular based centroids of these subtypes, and hence the approach should not need the simultaneous profiling of a group of cases for classification. An SSP would therefore have clinical utility, similar to other simple biomarkers currently used in diagnostic practice, to classify tumours into clinically meaningful groups (e.g. with distinct response to therapy, risk of relapse and/or outcome). In practice, SSPs have some limitations, including low concordance rates on sample assignment across several studies [25] [26]. In particular a lack of concordance was observed amongst the assignment of tumours into Luminal A, Luminal B and HER2 subtypes. These findings were further supported by those of a meta-analysis from a diverse set of different microarrays which showed a limited concordance of SSPs in 22 uniformly pre-processed datasets in 4000 hybridizations [27] . Based on these findings, the reliability of single sample predictors has been brought into question, which could be based on the bioinformatics algorithms used for classifications [28] (Figure 3 ) and/or be due to the biological nature of disease, which in the case of luminal/HER2 tumours is a spectrum of disease rather than being discrete entities that are easily stratified.
An alternative approach is the development of subtype classification models (SCM), which have an advantage over SSPs in their versatility. An SCM can be applied to different microarray platforms and a variety of normalisation methods [29] [30] [31] [32] . To illustrate this concept, a subtype classification model was developed using a mixture of three Gaussian distributions representing three important breast cancer phenotypes (ER, HER2 amplification signalling and cell proliferation) in a two-dimensional space [29, 32] (Figure 3) . The model consisted of co-expression gene modules representing these phenotypes, each consisting of genes associated with the key biological process.
These ER, HER2 and proliferation co-expression gene modules were derived from a meta-analysis of 2,833 breast tumours, using a multiple regression approach with a Gaussian error model. For example, the ER gene module consisted of a set of 288 genes with correlated expression to ESR1; similarly there were 20 genes in the HER2 module and there were 355 genes in the proliferation module [29] . These modules were refined to a single three-gene subtype classification module using the 3 original prototype genes (ESR1, ERBB2 and AURKA) in 5715 tumours [32] . In a comparative analysis in this large dataset, three different SCM classifiers, including the three gene SCM, were compared to three SSPs for molecular subtypes classification; the SCMs were shown to be more robust than SSPs at subtype classification and provided similar prognostic value [32] . Strong correlations of the raw prediction scores were observed in tumours profiled with different technologies (i.e. Affymetrix microarray and Illumina RNA-seq) [33] , confirming that the subtype classifiers (SSPs and SCMs) can be transferred from microarray to RNA-seq technologies.
An analyst wishing to define a prognostic gene signature must also be aware of the fact that genes can be associated with outcome purely by chance. Enlightening research by Venet et al. revealed that randomly selected gene sets may be associated with breast cancer outcome, to some degree [34] . It is necessary, therefore, for robust checks to be implemented to ensure that a gene signature is unique in its ability to prognosticate compared to other randomly chosen genes that are prognostic by chance. The package Sigcheck has been developed to deal with this particular issue [35] (Table 2 ) and compares the performance of an identified gene signature against the performance of known and random signatures through permutation testing.
Commercially available mRNA-based diagnostic tests
There are several commercially available mRNA-based diagnostic tests for prognostication and prediction in breast cancer. These gene expression panel assays are risk predictors and examples include: MapQuantDX™ (Genomic Grade Index, GGI) [36] , ProSigna® [24] [37] , Mammaprint® [38], OncotypeDX® [39] and EndoPredict® [40] (Table 1) . Each predictor was derived in a different manner and using a unique algorithm, but collectively they classify the risk of recurrence of breast cancer, and hence provide insight into whether a patient might require adjuvant chemotherapy or not. From a bioinformatic point of view, the original implementations of the mRNA signatures are available in the R programming environment through the package genefu [41] . This is therefore a particularly useful package, the 'swiss army knife' of gene expression signatures and can be added to any bioinformatics analysis pipeline (Table 1) to enable in silico comparison between these established signatures and novel metagene sets using publically available gene expression data.
The Genomic Grade Index (GGI; MapQuantDX™) is an RT-PCR-based assay that can be applied to formalin fixed, paraffin embedded (FFPE) tissues and is performed by a centralised laboratory to predict the risk of distant recurrence in ER-positive breast tumours. The GGI was first developed through testing the hypothesis that gene expression profiling could add value to conventional histological grading. Grade 1 and 3 tumours exhibit low and high risks of recurrence, respectively, and hence patients can be managed with some confidence. However, patients diagnosed with grade 2 disease are more challenging to manage and so the intent with the GGI was specifically in stratifying grade 2 tumours into good (grade 1-like; low risk of recurrence) and poor (grade 3-like; high risk of recurrence) prognostic groups [36] .
This tool was derived from a total set of 64 ER positive tumour tissue samples and a comparison was performed between grade 1 and grade 3 tumours using a differential gene expression analysis. The GGI score was determined through the difference of the log-transformed gene expression values of grade 3 and grade 1 associated genes. The tumour cohort was scaled and normalised further using offset parameters finally revealing a total of 97 genes [36] , which were validated in an independent set of 125 patients as being able to stratify grade 2 tumours into grade 1-like and grade 3-like. A cut-off point of the GGI score was determined rather than utilising GGI as a continuous score, whereby high risk was defined as (GGI ≥0) and the low-risk group was defined as (GGI<0). The GGI was investigated alongside other signatures in a large cohort of 2833 patients, highlighting the importance of proliferation-associated genes in breast cancer prognostication [29] . Subsequent evaluation in various clinical cohorts demonstrated the utility of this signature, relative to other measures of a tumours proliferative capacity (Ki67 staining, histological grade, mitotic activity) for predicting disease free survival [42] [43] [44] [45] [46] [47] .
ProSigna® is the commercial iteration of the PAM50 subtyping tool, and generates a risk of recurrence score primarily to predict chemotherapy benefit [21, 24, 37, 48] .
ProSigna® is applied using the nanoString nCounter Analysis System, to obtain digitally quantified gene expression levels, even for archival (FFPE) tumour material. A prognostic risk model was developed by applying the PAM50 subtype predictor in combination with various clinical-pathological parameters (tumour size and grade), to a series of published breast cancer datasets, including the 141 cases of node negative, untreated disease from the NKI cohort that was previously used to develop Mammaprint [21, 38] . The risk of recurrence (ROR) score (combination of PAM50 plus clinical parameters) outperformed the use of clinical parameters alone or molecular subtype classification alone for predicting outcome [21] . The PAM50 assay was validated in the ABCSG-8 trial as a prognostic tool for distant recurrence-free survival (DRFS) [49] . This trial consisted of a set of 1478 patients with postmenopausal, early stage ER positive breast cancer who received endocrine therapy [49] . All examples of the 4 intrinsic subtypes were present in this cohort, as were all ProSigna risk groups (i.e. low, intermediate and high). Patients had a probability of 10 years DFRS of 96.7% when classified as low risk, 91.3% for intermediate risk and 79.9% for high risk [49] , showing the clinical value of this gene signature. Importantly, ProSigna is suitable for use in core needle biopsies in the neoadjuvant chemotherapy setting [48] and has also revealed an accurate estimation of the risk of distant recurrence in estrogen receptor-positive (ER+), node-negative patients treated with five years of adjuvant tamoxifen, [24] .
MammaPrint® is a microarray-based 70-gene assay that is performed by a centralised service on fresh frozen tumour material. The set of 70 genes were originally derived using 98 patients, 34 of which developed metastatic disease and 44 were metastasis free after 5 years follow up [38] . The neat hypothesis underpinning its development was that the expression of a unique set of genes could distinguish between a good and poor prognosis. The transcriptome was profiled and a filtered set of approximately 5000 genes were obtained based on their ≥2.5 fold differential expression between the 'metastasis' and 'no metastasis' groups at a statistical significance of p<0.01 [38] . A supervised classification model was then generated after extensive feature selection these patients would ordinarily have been given chemotherapy, yet, since patients were classified as low-risk based on the gene signature, they were not given chemotherapy. The rate of 5-year survival was 94.7% in this clinically and genomic discordant risk group [51] , suggesting that using the genomic risk predictor to identify low-risk patients might be clinically useful in recognising a target population that will have a good prognosis without chemotherapy, despite having contrary clinical indicators of high-risk disease.
OncotypeDX® is a 21-gene panel that was derived using a unique approach; a high throughput Real-time PCR (RT-PCR) approach was used to quantify the expression of a targeted panel of 250 candidate genes identified through a combination of literature analysis, genomic-focused databases, pathway analysis and from the analysis of publically available microarray gene expression profiling data [39] . The expression level of these genes was examined in three independent cohorts [52] [53] [54] 
DNA Signatures in Breast Cancer
All cancers are characterised by the acquisition of somatic mutations to the tumour genome, including base substitutions, insertions and deletions, copy-number changes and structural rearrangements. The diversity of this "genomic landscape" among individual tumours is considerable. Some alterations directly affect key cancer genes A range of copy number-based classifiers have been determined for breast cancer [72] , including using variants of random forest [73] , logistic regression, logistic group lasso [74] , fused support vector machine (SVM) [75] and supervised and unsupervised feature clustering (FC) using silhouette methods for estimating clusters [76] . Both unsupervised and supervised FC performed the best at classifying aCGH data from tumour samples, as a result of their ability to remove unwanted correlation bias [72] .
Compared to other methods tested this approach allowed more accurate features to be selected and as a result, greater accuracy could be achieved [72] . This highlights the 
Computational methods for classifying mutation signatures
Deciphering the signatures of mutational processes in cancer genomes is a blind source separation problem [81] . This problem involves unravelling hidden signals in a mixture of various signals, without knowing the mixing that was performed. The intrinsic non-negative nature of the blind source separation problem requires an algorithm that assumes non-negativity of the original source of the signal [81] . The primary algorithms for identifying mutational signatures are non-negative matrix factorization (NMF) and variants, for instance BayesNMF. There is a two pronged approached to NMF; the first approach is to determine the signatures that best account for mutational observations. This approach is achieved through mathematical optimization implemented to identify factors at a fixed rank of the actual number of signatures and a chosen norm. The second approach is to determine the actual number of signatures and this is achieved by further factorising the same data and applying a ranking system for different numbers of signatures and the appropriate rank is determined by identifying the clustering properties of the factors obtained from the original algorithm [82] . The NMF signature discovery approach is now available in the R package somaticsignatures [83] , which includes visualisation tools ( Table 2 ). The Bayesian non-negative matrix (BayesNMF) variant is available here (http://archive.broadinstitute.org/cancer/cga/msp). BayesNMF offers analytical utility, as you do not have to initially define the number of signatures. An optimal number of signatures is determined directly from the data, striking the balance between data fidelity and the model complexity [84] [85] [86] . Simple model-based approaches of signature identification and visualisation are also available (probabilistic mutation signature -pmsignature), and differ from the usual NMF approach [87] (Table 2) . [87] . Each mutational signature is characterized by the probability distribution for each feature. The decomposition is then analysed using a probabilistic model, which assumes each feature is independent and significantly reduces the number of parameters to 18 per signature, unlike the 3071 parameters per signature employed by other methods [87] .
Both somaticsignature and pmsignature have their advantages and disadvantages (Table 2 ) in yielding mutational signatures that provide further insight into the mechanistic underpinnings of these mutational processes. However, the use of these tools is not yet widespread due to the cost and challenges associated with processing whole genome sequencing data. There is certainly precedence for these tools to be evaluated against each other, and for new tools that are more user-friendly to be
developed. An accurate mutational signature relies heavily on the accuracy of the variant callers; consequently, the robustness of these mutational signatures needs to be evaluated further in a hypothesis-driven fashion.
There are several limitations that need to be addressed in order to derive a full spectrum of mutational signatures. These limitations include the sample size, since at least 200 whole genome-sequencing samples were required to determine 20 mutational signatures [81] . The second limitation is sequencing coverage, as exome sequencing covers approximately 1% of the human genome so fewer mutations are identified and effectively a large number of samples are required to determine the majority of mutational processes [88] . In order to address this particular issue deconstructSigs was developed [88] . This tool reconstructs the mutational profile within a single tumour sample rather than relying on a set of tumour samples. A multiple linear regression model is implemented using the fraction of mutations found in each of the 96-trinucleotide contexts in each tumour as input. The approach determines the weights that will best recreate the input data. Signatures are excluded if a single trinucleotide context comprises more than 20% of the signature, which is not present in the input data [88] . The reason for this exclusion is that some signatures are characterised largely by specific trinucleotide contexts and if these contexts are absent in the input data then the signature is unlikely to be active [88] . An initial mutational signature is chosen from the remaining signatures that best encompasses the mutational profile in a single tumour. A forward selection process then determines the optimal weight for each signature based on the contribution of the signature to the reconstructed profile. The weight corresponding to that minimizes the sum squared error between the tumour sample and the reconstructed profile is subsequently selected. The weights are normalized to 0 and 1 and a reconstructed tumour profile is constructed based on the remaining weights [88] .
Clinical Utility of Mutation Signatures
The clinical relevance of genome-scale patterns of DNA alterations has been investigated to gain an understanding of the mechanistic underpinnings of tumour aetiology, but also in particular to raise the possibility that genome profiling might be a useful clinical/diagnostic tool to aid patient management.
In addition to the work described above, where substitution signatures of know aetiology can give insight into causes of some cancers (e.g. smoking, ultraviolet irradiation, DNA repair deficiency), a recent pioneering study examined the impact of ionizing radiation (IR) as a cancer-causing agent. The investigators identified patients who received radiotherapy in order to treat a cancer (of any type), but who then developed a second tumour within the field of the therapeutic IR. Whole genome sequencing of the second tumours revealed two unique patterns of mutation signature specifically associated with in vivo exposure to IR [89] . These mutation patterns involved a high rate of small (1-100 bp) deletions and balanced inversions, distributed throughout the genome, irrespective of the type of tumour analysed. This study gives in vivo insight into the precise role of IR in causing mutations to normal cells in the field of IR, which initiated the malignant process.
Patterns of DNA alterations (loss of heterozygosity and copy number alterations) and DNA mutational signatures are also being developed as diagnostic tools to help stratify patients into certain treatment actionable groups. One area of great interest is in identifying tumours with homologous recombination (HR) deficiency. Between 1-5% of breast cancers are attributable to germline mutations in BRCA1 and BRCA2, and as described above these tumours exhibit considerable genome instability indicative of HR deficiency. Importantly, BRCA1/2 deficient tumours also exhibit enhanced sensitivity to some DNA damaging chemotherapies, particularly platinumbased compounds, or to targeted therapy using inhibitors to poly(ADP-ribose) polymerase (PARP) [90] . HR-deficient tumour cells exhibit considerable sensitivity to PARP inhibitors because PARP is involved in an alternative repair pathway called base excision repair (BER). Hence, with BER inactivated, single strand breaks are not effectively repaired and they accumulate as double strand breaks during DNA replication, leading to replication fork collapse, enhanced genome instability and cell death. Genome-scale patterns could therefore be a biomarker of HR deficiency and hence sensitivity to PARP inhibitors or certain chemotherapies. Great interest has therefore been applied to develop 'biomarkers' of HR deficiency based on the pattern of somatic alterations identified in the tumour genome. These genome-based 'tools' utilise either aCGH or SNP array based genome data [64] [65] [66] [67] [68] [69] [70] [71] or more recently whole genome sequencing data [91] .
Several genome stability scores have been developed that use combinations of DNA copy number and/or allelic imbalance information to infer HR deficiency. For example, telomeric allelic imbalance (AI) is a subchromosomal region of AI that extends to the telomeric end of a chromosome. The number of telomeric AIs was associated with sensitivity to platinum-based therapy in triple negative breast cancer [71] . In another study, the total number of breakpoints within a tumour genome had no association with BRCA status, however the number of large-scale transitions (LST), defined as chromosomal breaks between adjacent regions of at least 10 Mb correlated with BRCA1 inactivation [69] . Loss of heterozygosity (LOH) was also strongly associated with BRCA deficiency [68] . These three genome-based scores (telomeric AI, LST and LOH) have been assessed as a combined homologous recombination deficiency (HRD) score (HRD Index) in various cohorts of breast cancer samples. The assay, developed using next generation sequencing, was collectively a more sensitive predictor of BRCA deficiency than individual parameters [92] and identified patients with increased benefit to neoadjuvant platinum based therapy [66, 93] . Similar findings have been reported reflecting the burden of allelic imbalanced copy number alterations and response to platinum-based chemotherapy [70] .
A recent study applied whole genome sequencing data of breast cancers to develop a probabilistic predictor of HR deficiency [91] . Logistic lasso regression modelling was used to incorporate six genomic parameters, including substitution and rearrangement signatures and the HRD Index (described above) into a predictor, termed HRDetect.
The predictor identified 22% of all breast tumours as being HR deficient, including tumours with germline or somatic biallelic inactivation of BRCA1/2, but also tumours in which the cause of the HR deficiency was unclear. In a small pilot, the HRDetect score correlated with pathological response to neoadjuvant anthracycline chemotherapy [91] . This collective data indicates the potential for complex genomescale mutation data to be distilled into a simple diagnostic score that could be used clinically to identify patients who may gain benefit from certain chemotherapies or PARPi.
Intratumour heterogeneity is a consequence of the acquisition of DNA mutations that drive the evolution of tumour cell clones with enhanced 'fitness'. It is important to consider that the selective pressures of therapy may promote the accumulation of favourable mutations that lead to the development of treatment-resistant clones. The APOBEC substitution signature [43, 94] is a marker of APOBEC mutagenesis and has been linked to ensuing tumour evolution during progression and as a mechanism of resistance to treatment [95] . In breast cancer, a study has revealed that APOBEC3B
could be a potential biomarker of tamoxifen resistance in ER+ disease [96] . The levels of ABOPEC3B in primary ER+ tumours inversely correlated with clinical benefit from tamoxifen treated metastatic disease. This finding was also validated in vitro using functional manipulation of APOBEC3B levels to either enhance tamoxifen response when APOBEC3B was depleted or to enhance resistance when APOBEC3B
was overexpressed [96] .
Pioneering work using whole genome sequencing data has also identified a novel phenomenon known as kaetaegis [97] , which is defined as clusters of mutations or hypermutation in concentrated genomic regions. Recent work has linked a 628 kaetaegis gene expression signature to higher grade breast tumours that are HER2
positive and have prolonged survival [98] . This study derived a signature based on a differential gene expression analysis between kaetaegis breast tumours and 106 normal breast samples. The expression of genes proximal and distal to kataegis loci was reported. From these studies, it is clear that integration of the findings from whole genome sequencing data and transcriptomic data will reveal key signatures that explain breast cancer prognosis and disease aetiology.
Certainly, the area of cancer genomics has advanced significantly in recent years.
Some of the findings highlighted here suggest that the unique insights being derived from different types of mutational profiling are revealing important insights into tumour biology, but also that they could make major contributions in the clinical management of patients, for example in the context of novel biomarkers that might predict therapeutic response.
Conclusions
There are increasing numbers of molecular signatures that are already commercially 
